Opinion

Video

Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Video Player is loading.
Current Time 0:00
Duration 5:52
Loaded: 0%
Stream Type LIVE
Remaining Time 5:52
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • For a patient who does not receive second-line cellular therapy whether based on logistical or clinical reasons, what would be your choice of approved therapies?
    • When choosing a second-line therapy for a patient not eligible for transplant or CAR T-cell therapy, what most impacts your decision? Drug approval? NCCN guidelines? Based on what first-line treatment was received?
  • Please review the final 5-year data of the L-MIND study evaluating tafasitamab + lenalidomide.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Content